XML 40 R27.htm IDEA: XBRL DOCUMENT v3.19.2
Collaboration and Other Agreements - Incyte (Details)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Oct. 31, 2017
USD ($)
Jun. 30, 2019
USD ($)
Jun. 30, 2018
USD ($)
Dec. 31, 2017
USD ($)
performance_obligation
Jun. 30, 2019
USD ($)
Jun. 30, 2018
USD ($)
Dec. 31, 2018
USD ($)
Collaboration And Other Agreements [Line Items]              
Revenues   $ 10,593 $ 18,834   $ 20,255 $ 23,529  
Incyte Corporation | Incyte MGA012 Agreement              
Collaboration And Other Agreements [Line Items]              
Non-refundable upfront payment       $ 150,000      
Potential development and regulatory milestone payments under agreement $ 420,000            
Potential commercial milestone payments under agreement 330,000            
Development and regulatory milestones recognized         15,000   $ 15,000
Number of performance obligations | performance_obligation       2      
Collaborative agreement transaction price 154,000            
Variable consideration recognized $ 4,000            
Maximum | Incyte Corporation | Incyte MGA012 Agreement              
Collaboration And Other Agreements [Line Items]              
Proceeds from royalties (percent) 24.00%            
Minimum | Incyte Corporation | Incyte MGA012 Agreement              
Collaboration And Other Agreements [Line Items]              
Proceeds from royalties (percent) 15.00%            
Revenues From License Agreements | Incyte Corporation | Incyte MGA012 Agreement              
Collaboration And Other Agreements [Line Items]              
Revenues $ 150,000       8,200    
Revenues From License Agreements | Incyte Corporation | Incyte MGA012 Agreement - Clinical activities              
Collaboration And Other Agreements [Line Items]              
Revenues   0 600   $ 100 3,100  
Revenues From License Agreements | Incyte Corporation | Incyte MGA012 Agreement - Services              
Collaboration And Other Agreements [Line Items]              
Revenues   $ 4,200 $ 9,900     $ 9,900